Trial NCT02876640

Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer

This phase 1b trial studies the biologic effect of 9cUAB30 on early stage breast cancer.
9cUAB30 is a retinoid X receptor (RXR)-selective retinoid that acts in a tissue selective
manner with the goal of minimizing side effects, a necessary feature of agents under
development for cancer prevention.

Intervention

Retinoid 9cUAB30, Therapeutic Conventional Surgery

Condition

Early-Stage Breast Carcinoma, Invasive Breast Carcinoma

Investigators

Sonia L. Sugg, Jane Yuet Ching Hui, Helen Krontiras, Lee G. Wilke

See list of participating sites